Cookie Policy

We've put some small files called essential cookies on your device to help our site work on your browser.
We also use analytical cookies to help up improve our website by collecting and reporting information on it's usage.

You can read more above this on our Privacy Policy page.

I'm ok with analytical cookies Do not use analytics cookies
Contact us

Our Products

Our clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make the difference in their everyday lives.

A commercial stage, pharmaceutical company delivering innovative speciality pharmaceuticals that address patients’ unmet medical needs, with an initial focus on addressing anaemia associated with renal and gastrointestinal disorders.

Accrufer® / Feraccru®

Our lead product is approved for the treatment of iron deficiency with or without anaemia in adults in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid 2030s.

In Europe the product is marketed as Feraccru® with commercialisation led by Norgine BV. In the USA – where the product also benefits from NCE exclusivity until 2020 – it is marketed as Accrufer®.

We also have an exclusive licence agreement with ASK Pharm, who will lead the development and commercialisation in China.

Read more

Pipeline product candidate

Please click here for more information on PT20.

Read more

Pipeline